Related references
Note: Only part of the references are listed.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles
A. J. Krentz et al.
DIABETES OBESITY & METABOLISM (2016)
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
Yasushi Honda et al.
PLOS ONE (2016)
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
Chikara Komiya et al.
PLOS ONE (2016)
Analysis of renal functions and proteinuria in young obese adults
D. -Y. You et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2015)
A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes
Luke D. Boyle et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Diacylglycerol Acyltransferase-2 (DGAT2) and Monoacylglycerol Acyltransferase-2 (MGAT2) Interact to Promote Triacylglycerol Synthesis
Youzhi Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
J. P. H. Wilding et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Macrocytic Anemia and Thrombocytopenia Induced by Orlistat
David Palacios-Martinez et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2013)
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Yin Liang et al.
PLOS ONE (2012)
Murine Diacylglycerol Acyltransferase-2 (DGAT2) Can Catalyze Triacylglycerol Synthesis and Promote Lipid Droplet Formation Independent of Its Localization to the Endoplasmic Reticulum
Pamela J. McFie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Auraptene regulates gene expression involved in lipid metabolism through PPARa activation in diabetic obese mice
Nobuyuki Takahashi et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2011)
Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a Western-style diet by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels
Yan-wen Qin et al.
ACTA PHARMACOLOGICA SINICA (2010)
Sugar-Sweetened Beverages, Obesity, Type 2 Diabetes Mellitus, and Cardiovascular Disease Risk
Vasanti S. Malik et al.
CIRCULATION (2010)
Time-course comparison of xenobiotic activators of CAR and PPAR alpha in mouse liver
Pamela K. Ross et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2009)
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Raj S. Padwal et al.
LANCET (2007)
Weight gain induced by high-fat feeding involves increased liver oxidative stress
Fermin I. Milagro et al.
OBESITY (2006)
The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice
AM Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
The metabolic abnormalities associated with non-alcoholic fatty liver disease
M Haque et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2002)
Share Paper
